Product Description
ZW191 is an antibody-drug conjugate that is engineered to target a protein called folate receptor-⍺ (FR⍺) that is found on a variety of tumours. ZW191 delivers a toxic chemotherapy, topoisomerase-1 inhibitor, to these tumour cells to kill the cancer. (Sourced from: https://www.zymeworks.com/pipeline/)
Mechanisms of Action: FOSL1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zymeworks
Company Location: Vancouver A1 V6H 3V9
Company CEO: Kenneth Galbraith
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, Korea, Poland, Singapore, Spain, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Endometrial Cancer|Non-Small-Cell Lung Cancer|Ovarian Cancer|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2031240343 | P1 |
Recruiting |
Ovarian Cancer|Non-Small-Cell Lung Cancer|Endometrial Cancer |
2027-05-31 |
|
| ZWI-ZW191-101 | P1 |
Recruiting |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Endometrial Cancer|Ovarian Cancer |
2026-12-01 |